Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
CNS myelin wrapping is driven by actin disassembly.
Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging.
Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation.
IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis.
The mystery of missing heritability: Genetic interactions create phantom heritability.
Ustekinumab.
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.
FTY720 in patients with primary progressive multiple sclerosis (INFORMS)
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis.
Prospective memory, emotional valence, and multiple sclerosis.
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.
Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord.
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
Remyelination therapy goes to trial for multiple sclerosis
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility.

Pages